InFLUenza and the HEART An Investigation Into the Acute and Lasting Cardiac Effects of Influenza Infection (FluHeart)

May 1, 2026 updated by: Tor Biering-Sørensen, University Hospital, Gentofte, Copenhagen

Influenza and the Heart: An Investigation Into the Acute and Lasting Cardiac Effects of Influenza Infection

"Influenza and the Heart: An investigation into the acute and lasting cardiac effects of influenza infection" the investigators aim to assess the mechanisms for cardiovascular disease in patients suffering an acute influenza infection. The project will be carried out by creating a prospective clinical cohort study of consecutive patients hospitalized at Herlev & Gentofte University Hospital with a laboratory confirmed influenza.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

241

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Tor Biering-Sørensen, MD

Study Locations

      • Copenhagen, Denmark, 2900
        • Herlev & Gentofte Hospital
      • Hellerup, Denmark, 2900
        • Cardiovascular Non-Invasive Imaging Research Laboratory, department of Cardiology, Herlev & Gentofte Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Hospitalized patients with laboratory confirmed influenza

Description

Inclusion Criteria:

  • All patients hospitalized at Herlev & Gentofte University Hospital with a laboratory-confirmed diagnosis of influenza
  • > 18 years of age

Exclusion Criteria:

  • Persons not able to cooperate
  • Persons unable to understand and sign "informed consent"
  • Pregnancy
  • Persons simultaneously positive with COVID-19

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of patients developing cardiovascular complications
Time Frame: 3 years
Including new-onset heart failure, worsening of current heart failure, acute myocardial infarction, and cardiac arrest
3 years
Number of patients developing in-hospital mortality
Time Frame: 3 years
3 years
Rate of cardiac dysfunction
Time Frame: 3 years

Defined by impaired echocardiographic parameters and elevated cardiac biomarkers - NT

- pro

- BNP annd hs

- TNT

3 years
Prevalence of elevated biomarkers of infection/inflammation
Time Frame: 3 years
Prevalence of elevated biomarkers of infection/inflammation and it association with cardiac dysfunction
3 years
Rate of pulmonary embolisms diagnosed with CT thorax angiography
Time Frame: 3 years
3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2022

Primary Completion (Actual)

May 1, 2024

Study Completion (Actual)

June 1, 2024

Study Registration Dates

First Submitted

October 6, 2021

First Submitted That Met QC Criteria

October 6, 2021

First Posted (Actual)

October 20, 2021

Study Record Updates

Last Update Posted (Actual)

May 4, 2026

Last Update Submitted That Met QC Criteria

May 1, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • H-21011835

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Influenza

Search Similar Trials